NeoFox revised study plan approved
The Spanish regulatory authorities have approved the revised study plan for the phase 2 NeoFox study for the drug candidate Foxy-5.Due to the reported unexpectedly rapid positive observations with Foxy-5, the study plan for the phase 2 NeoFox study has been revised. The change is now approved by both The Spanish Agency for Medicines and Medical Devices and the Central Ethical Review Committee in Spain, where the majority of the participating clinics are located. The change means that new end points will be introduced at the patients' surgery, to show the effects previously observed in an